Evidence map›Paper›PMID 41809094›Full record

ArticleBioactive materials2026

A foam cell-targeted lipophagy restoration strategy stabilizes vulnerable atherosclerotic plaques.

Heng Li, Yusheng Qin, Jianhong Zhang, Xinlin Guo, Xiaolin Hu, Danlei Sun, Yue Zhao, Sergio Bernardini, Daqian Xu, Peng Jiang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Heng LiDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Yusheng QinDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Jianhong ZhangDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Xinlin GuoDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Xiaolin HuDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Danlei SunDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Yue ZhaoDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Sergio BernardiniDepartment of Experimental Medicine, University of Rome Tor Vergata, Italy.
Daqian XuZhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Peng JiangState Key Laboratory of Molecular Oncology, School of Life Sciences, Tsinghua University, Tsinghua-Peking Center for Life Sciences, Beijing, China.
Hong ZhangDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.
Yang LuoDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in therapies for atherosclerosis, the limited efficacy in reversing vulnerable atherosclerotic plaques remains a significant challenge in translational cardiovascular research. We developed OPN-HMCN@MLT, a targeted nanoplatform combining melatonin (MLT) with an osteopontin (OPN)-binding peptide and hyaluronic acid-modified mesoporous carbon. By exploiting the acidic, HAase-overexpressing, and OPN-enriched microenvironment of vulnerable plaques, this system enables cascade-responsive drug release triggered sequentially by OPN recognition, HA degradation, and acidic pH. This system enables precise plaque targeting and label-free photoacoustic (PA) imaging, exploiting the intrinsic imaging capacity of carbon carriers while enhancing MLT's bioactivity. Elevated OPN expression in foam cells facilitates selective retention of OPN-HMCN@MLT in vulnerable lesions, resulting in enhanced plaque-associated PA signals.

Indexed as

LipophagyMelatoninMesoporous carbonPhotoacoustic imagingVulnerable atherosclerotic plaque

Identifiers

PMID41809094
PMCPMC12969391

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.